Stock Analiz

Black Diamond Therapeutics, Inc. BDTX

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2020 · data as of November 13, 2026

$1.47Market cap $84M
Open the interactive analysis →

Black Diamond Therapeutics, Inc. (BDTX) is a healthcare company listed in the US with a market value of about $84M. In fiscal year 2025 it had revenue of $70M and net income of $22M, a net margin of 32.0%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is financial health (3/5); the weakest is future growth (0/5).

Key numbers: a 5-year average ROIC of -39%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 278% above the current price.

About Black Diamond Therapeutics

Black Diamond Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2020. It was profitable in 1 of the last 8 years in our data. Its share count rose by 58% over three years (dilution for shareholders). It spends 48% of revenue on research and development.

Score: 1.0 / 5

Value1/5
Future growth0/5
Track record1/5
Financial health3/5
Shareholder returns0/5

Checks passed

  • Price below intrinsic value (DCF, moderate assumptions)
  • ROE above 15%
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B1.0
EV/EBITDA—
PEG—
Dividend yield—
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price+278%

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)31.9%
ROIC (5-yr avg.)-39.0%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 8 years

Fiscal year20252024202320222021202020192018
Revenue$70M$0———$0$0$0
Net income$22M-$70M-$82M-$91M-$126M-$67M-$35M-$9M
Free cash flow—-$62M-$67M-$85M-$103M-$52M-$25M-$9M
EPS (diluted)$0.39$-1.27$-1.88$-2.52$-3.47$-2.05$-16.99$-4.42
Net margin31.9%———————
ROIC7.5%-59.0%-48.1%-51.0%-44.5%-17.4%——

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Black Diamond Therapeutics stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 278% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Black Diamond Therapeutics pay a dividend?

Not currently.

Is Black Diamond Therapeutics a good stock to buy?

We do not give buy or sell advice. Black Diamond Therapeutics scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.